Feature | October 30, 2012

Enrollment Completed for Elixir DESolve Nx Pivotal Trial for Fully Bioresorbable Coronary Stent

Results from DESolve I study for fully bioresorbable coronary scaffold system presented at TCT

DESolve Nx Pivotal Trial Bioresorbable Coronary Stent Elixir Cath Lab

October 30, 2012 — Elixir Medical Corp. said enrollment is complete in its 120-patient, pivotal clinical trial evaluating the safety and efficacy of the DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold System. The scaffold is designed to resorb in the body within one to two years after implantation and return the patients’ coronary vessel to de novo state. Patient follow-ups are expected to be completed by year-end.

The primary safety endpoint of the DESolve Nx trial is the composite of major adverse cardiac events (MACE) comprising cardiac death, target vessel myocardial infarction (MI) and clinically-indicated target vessel revascularization (TLR). The primary angiographic endpoint of the trial is in-stent late lumen loss at six months as assessed by QCA (quantitative coronary angiography). In a subset of patients, additional QCA assessment will be conducted at 24 months; stent and vessel assessment using IVUS (intravascular ultrasound), OCT (optical coherent tomography) will be conducted at baseline, six and 24 months; and MSCT (multi-slice computed tomography) at 12 months, thus providing long-term assessment of the scaffold and surrounding vessel.

“Bioresorbable drug-eluting scaffolds that effectively treat the coronary artery obstruction without leaving a permanent metallic implant behind in the long term are undoubtedly the next frontier for interventional cardiology,” said Stefan Verheye, M.D., Ph.D., ZNA Middleheim Hospital, Antwerp, Belgium, and principal investigator of the DESolve Nx study. “Having used the DESolve bioresorbable scaffold system in two clinical studies, and observed its impressive performance, I am confident that Elixir’s DESolve scaffold system can achieve and maintain excellent long-term clinical outcomes.”

The DESolve scaffold made from a proprietary and proven poly-L lactide (PLLA)-based polymer provides optimal strength and support to the artery while delivering the novel anti-proliferative drug, Novolimus. Some unique features of the DESolve scaffold design as demonstrated in preclinical testing include: the ability to self-appose to the vessel wall in cases of malapposition; the ability to maintain radial strength and vessel support for the critical period of vessel healing while bioresorbing within 12 to 24 months; and a wide margin of scaffold expansion without strut fracture.

The multicenter, prospective DESolve Nx trial was designed to enroll 120 patients at 15 centers in Germany, Belgium, Poland, Brazil and New Zealand. Enrollment completion of this DESolve Nx trial follows outstanding results of Elixir’s DESolve first-in-man study wherein at six months, Elixir’s DESolve demonstrated excellent late lumen loss of 0.19 ± 0.19 mm, no artery blockage (0.0 percent binary restenosis), no late malapposition (0.0 percent), low acute recoil (6.4 percent ± 4.3), no cases of blood clots (0.0 percent stent thrombosis) and a single MACE event due to a stenosis in the segment 5 mm proximal to the scaffold, which itself was widely patent.


Successful Live Case Follow-Up of DESolve Nx Patient at TCT 2012 in Miami

Professor Alexandre Abizaid, M.D., Ph.D., The Instituto Dante Pazzanese de Cardiologia, Brazil, conducted a successful live case from Sao Paulo of a patient enrolled in the DESolve Nx trial undergoing six-month follow-up. The angiographic, IVUS, OCT, and MSCT imaging of the coronary vessels treated with the fully bioresorbable DESolve Novolimus-Eluting Coronary Scaffold was projected live in the main arena at the 24th annual Transcatheter Therapeutics (TCT) conference. The coronary vessels of the patient were widely patent, and these excellent results were well received by an expert panel of cardiologists gathered in Miami.

Bioresorbable scaffold technology had thus far been a challenge in the industry because it required a level of strength and support that only permanent metallic stents had been able to provide, the safe and gradual bioresorption of the scaffold once the blood vessel healed, and excellent clinical outcomes. The bioresorbable DESolve Novolimus-Eluting Coronary Scaffold holds the promise to overcome these challenges.


One-Year Results from DESolve I First-In-Man Study for Fully Bioresorbable Drug Eluting Coronary Scaffold System

Elixir Medical also announced one-year MSCT results at the “Next-Generation DES and Bioabsorbable Scaffolds” session at TCT for the 15-patient first-in-man clinical study of the fully bioresorbable DESolve coronary scaffold system, which were presented by Stefan Verheye, M.D., Ph.D., principal investigator of the study.

MSCT is a powerful noninvasive diagnostic modality to visualize coronary arteries and the manifestations of coronary disease. At one year, coronary vessels treated with Elixir’s DESolve maintained their mean minimum lumen diameter (MLD) at 2.4 ± 0.4 mm, with a percent diameter stenosis (percent DS) of 15.9 ± 10 percent as measured by MSCT. These results confirm the sustained efficacy of Elixir’s DESolve, which had demonstrated excellent results at the six-month angiographic follow-up with a mean MLD of 2.41 ± 0.28 mm and percent DS of 12.63 ± 11.37 percent.

“The DESolve bioresorbable scaffold system for the treatment of artery disease will become the new standard for vascular intervention,” said Motasim Sirhan, CEO of Elixir Medical.

Elixir said at TCT that it plans to start a U.S. Food and Drug Administration (FDA) investigational device exemption (IDE) trial in the United States after the stent is approved for use in Europe. The company is already in preliminary discussions with the FDA.

For more information: www.elixirmedical.com

Related Content

New Blood Test Predicts Major Cardiac Events Better Than Clinical Evaluation of Other Common Risk Factors
News | Blood Testing| April 28, 2017
Prevencio Inc. announced the publication of data demonstrating that a simple new blood test is more accurate than...
Feature | Inventory Management| April 28, 2017 | Dave Fornell
Tracking cardiovascular device inventory in cath labs, electrophysiology (EP) labs and operating rooms (ORs) can be a
the Impella pVAD improves survival, mortality in AMI heart attack with cardiogenic shock
Feature | Hemodynamic Support Devices| April 28, 2017 | Dave Fornell
Recent clinical study data presented at the American College of Cardiology (ACC) 2017 meeting show new treatment prot
New Twelve-Month Data Show Efficacy of Pulsar-18 Bare Metal Stent
News | Stents Peripheral| April 28, 2017
Biotronik’s Pulsar-18 bare metal stent (BMS) has yielded high primary patency in a real-world setting, according to the...
New Hampshire Hospital Expands Vascular Care with Toshiba Medical's Infinix-I Sky +
News | Angiography| April 27, 2017
Wentworth-Douglass Hospital in Dover, N.H., installed Toshiba Medical’s Infinix-i Sky + angiography system in its...
Mercator MedSystems Announces First Enrollment in TANGO Trial for Below-the-Knee Vascular Disease
News | Peripheral Arterial Disease (PAD)| April 27, 2017
Mercator MedSystems Inc. announced the first patient enrollment into the TANGO (Temsirolimus Adventitial Delivery to...
News | Venous Therapies| April 26, 2017
A new Varicose Vein Registry has begun producing useful outcomes information, as reported in the May edition of the...
Twelve-Month Data Positive for Ranger Paclitaxel-Coated Balloon Catheter
News | Drug-Eluting Balloons| April 26, 2017
Boston Scientific announced results from the RANGER SFA trial for the Ranger Paclitaxel-Coated PTA Balloon Catheter at...
Body Weight Fluctuations Linked to More Deaths in People with Coronary Artery Disease
News | Cardiac Diagnostics| April 25, 2017
Repeated cycles of weight loss and gain may be linked to higher risk for stroke, heart attack and death in people with...
Overlay Init